Introduction
T he global financial crisis of 2007-08 and its consequences have had a severe long-term impact on many European economies. National economies, as measured by gross domestic product (GDP), were most negatively affected in 2009, however some European Union (EU) member states, especially Greece, are yet to recover fully. 1 Challenges arising from low or no economic growth, coupled with rising deficits and borrowing costs, impacted on the availability of resources for public spending, including for health, across Europe. 2 Thus, per capita public spending on health fell in several countries, with a small number experiencing sustained reductions during 2009-12, in particular Greece, Ireland and Slovenia, but also Italy, Portugal, Spain and the UK. 3 The slowdown in health spending impacted upon the provision of health services 4 and access to care, 5 with large increases in unmet medical need observed in Greece, Estonia and Latvia during and following the crisis. 1 Other evidence points to an increase in the proportion of European citizens aged 50 years and older who incurred a rise in out-of-pocket expenditures during the same period, with significant increases in the proportion of those experiencing catastrophic expenditures in the Czech Republic, Italy and Spain. 6 It is plausible that these barriers to accessing care impact health outcomes, while reduced public health spending may result in deterioration of quality of care. At the same time, a well-functioning and resilient health system should be capable of maintaining adequate levels of services, unless gaps in financing, coverage or service delivery are unsurmountable.
As was demonstrated previously, [7] [8] [9] [10] European health systems have continued to contribute to improving population health by reducing deaths that can be avoided with timely and effective care (amenable mortality), a concept that is now used by several governments and international organizations as an indicator of health system performance. [11] [12] [13] [14] [15] The pace of improvement varied across countries, reflecting differences in the availability of and access to technologies and treatment, the effectiveness of service delivery and wider healthcare policies. In this study, we analyse amenable mortality trends from 2000 onwards in the countries of the EU in order to understand the possible impacts of the global financial crisis by means of Joinpoint regression analysis. We contrast amenable deaths with those where healthcare may have a less obvious impact (other mortality).
Methods

Definition
We used the list of conditions included in amenable mortality proposed by Nolte and McKee in 2004 (Supplementary appendix S1). 7 For consistency with previous work, we applied an upper age limit of 75 years and include 50% of ischaemic heart disease deaths as potentially amenable. We also measured 'other' mortality (all remaining causes) under the age of 75 years as a comparator to help interpret changes in amenable mortality.
Data and availability
We used the WHO detailed mortality files 16 to obtain data on the number of deaths in the 28 EU member states by country, year, sex and cause by 5-year age-group and the corresponding population denominators, for the years 2000-15. We calculated age-standardised mortality rates using the European Standard Population 2013. Mortality data for Italy (2004, 2005) and Portugal (2004-06) were not available and we only calculated trends from 2006 and 2007, respectively. Data for Greece included a change in ICD-coding of cause of death in 2014 (from ICD-9 to ICD-10). This resulted in marked changes in certain causes of amenable deaths, so we only used data for 2000-13 to examine trends over time.
Joinpoint regression
We used Joinpoint regression analysis to identify significant changes in mortality trends for amenable and other causes in each EU country, starting in 2000. We then identified countries which experienced significant reversal (flat-lining or increase) in amenable mortality in either males or females in or after 2009, while mortality from other causes continued falling. Although we recognize that economic crisis can also potentially affect mortality beyond amenable causes, trends in other causes provide a comparator between these two mortality groups, one of which is a widely recognized marker of health care sector performance. We performed further Joinpoint analysis on specific amenable causes of death in those countries where we found reversals in trends. The overall change in trend was measured in terms of annual percentage change (APC). We used Joinpoint Trend Analysis Software v4.5.0.1.
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Pre-and post-crisis period
The global financial crisis affected the economies of EU member states in or after 2008, with the earliest plausible impact on health service effectiveness and mortality expected in or after 2009. We therefore defined the years 2009 onwards as the post-crisis period, consistent with established usage. However, we recognize that the timing of the crisis differed across countries. 2 
Results
Overall, amenable and other mortality declined in all EU countries between 2000 and 2015. For amenable mortality, the average pace of decline varied between and APC of 0.4 in Lithuania to 5.6 in Ireland for males and between 1.8 in Lithuania and Italy to 5.0 in Ireland for females. The pace of decline of other mortality ranged from APC 1.2 in Bulgaria, Greece and Lithuania to 3.6 in Croatia and Slovenia for males and from 0.5 in Portugal to 4.6 in Cyprus for females. With the exception of Cyprus (females) and Lithuania (males), amenable mortality declined faster, on average, than other mortality (table 1) .
Since 2000, 30 Joinpoints in 18 countries were identified across both genders in amenable mortality trends. Most of these were related to amenable mortality displaying either more favourable, or a similar direction of change compared to other mortality (Supplementary appendix S2). There were only four instances of reversals in amenable mortality coinciding with the onset of the economic crisis (from decreases to 0 APC change or increases), against a background of a continued fall in other mortality. These were observed for females in Estonia (from À4. To better understand drivers of amenable deaths behind the postcrisis reversals, we performed Joinpoint analysis by cause of death for Estonia, Greece and Slovenia, for males and females (table 2) .
An observed reversal in female amenable mortality in Estonia was attributable, mainly, to a large relative increase in deaths from infectious diseases after 2012, on top of an underlying increasing trend in amenable deaths from respiratory conditions and treatable cancers since 2007. Among males, there was a small increase in amenable respiratory deaths, from 2011. A similar picture is seen in Slovenia, where a reversal in amenable mortality in females can be attributed to an increase in deaths from infectious diseases after 2010, accompanied by underlying slowing in the rate of decrease of amenable deaths from ischaemic heart disease after 2007, while the rate of reduction in other amenable causes remained consistent. Unlike in Estonia, there was a similar pattern among males in Slovenia, with a reversal in amenable deaths from infectious diseases after 2012, but also an underlying reduction in the pace of decline in deaths from ischaemic heart disease and respiratory conditions. Further examination of trends of infectious diseases found substantial recent rises in deaths from sepsis in both countries, although absolute numbers remain small (data not shown).
In Greece, amenable mortality reversed for males and females in 2010. This was driven by a complex set of changes, which also differed between males and females. Thus, the observed changes occurred against the background of small, but sustained increases in selected amenable causes of death since 2000. These included mortality from amenable infectious diseases, and from digestive and respiratory conditions among males and females, which rose at a pace of between 1 and 3% per year between 2000 and 2013. In addition, males experienced sustained increases in mortality from amenable cancers (APC 0.6) and diabetes (APC 1.1) from 2000 onwards. Mortality from stroke fell throughout the entire observation period but we observed a significant deceleration of the pace of decline that coincided with the crisis (from À7 APC in 2000-10 to À0.8 APC in 2010-13 in females and from À6. 
Discussion
This study found wide variations in both levels and pace of change in amenable mortality over time across EU member states. Although rates have, overall, declined, some countries experienced reversals in recent years, at least in the short-term. These are still fairly small in Estonia, Greece and Slovenia, but these countries have seen no increase in other mortality, suggesting that while overall population health is improving, health services may have experienced some challenges. However, observed trends have to be interpreted with caution as they affected males and females differently. In any case, a significant reversal in what has been a very longterm decline in mortality in any country should be a cause of concern, requiring further investigation. Amenable mortality, as used in this study, plays a dual role. First, it is one of the few existing indicators, which provides an initial assessment of the potential contribution of health services to population health. Second, as the outcome is deaths, it can help understand the impact of health system change. Although it is not possible, with aggregate data, to trace specific policies and actions affecting service delivery that lead to amenable deaths, it is known that the global financial crisis was associated with reduced access to care in multiple countries across the EU, particularly among more vulnerable groups. 18 Trends in amenable mortality in Estonia, Greece and Slovenia present a complex picture. First, while total amenable mortality in Estonia and Slovenia has reversed only in women after the crisis, cause-specific data show that men have also been affected, although to a lesser extent. In Estonia, the rise in amenable mortality in females was driven partially by an increase in mortality from infectious diseases, but this was not replicated in males. At the same time, rise in deaths from respiratory conditions seen across both genders was more pronounced in males, while both sexes experienced rise in mortality from other amenable conditions throughout the period. In Slovenia, the rise in deaths from infectious diseases was sharp in both genders in recent years, but only in females did it result in a pronounced change of direction in overall amenable mortality. It is important to note that deaths from infectious disease present a very small proportion of total amenable mortality, and absolute numbers are particularly low when disaggregated by gender in countries with small populations, such as Estonia and Slovenia. The increase in mortality from infectious diseases in both countries was driven by a rise in deaths from septicaemia, a trend seen in other European countries, such as the Czech Republic 19 and Serbia. 20 Explanations of these trends are complex, including population ageing and rising prevalence of complications of chronic diseases, while in Serbia the increase corresponded with the onset of the economic crisis. Suhrcke et al. 21 suggested various mechanisms by which economic crises can affect communicable disease control, such as through compromising the health of vulnerable population groups and placing additional pressures on health systems facing budgetary problems. However, the precise manifestations depended on the underlying epidemiological situation.
The effects of the measures imposed on Greece following the global financial crisis, including sustained reductions in public spending on health services, together with the broader impact of the crisis on population health, have been detailed elsewhere. [22] [23] [24] [25] This body of research has shown that while crisis in itself can pose real threats to health, particularly of vulnerable people, through unemployment and loss of income, the austerity measures to health system exacerbate the issue and further limit access to and quality of health care services. In terms of mortality outcomes, there is some limited research on selected causes of death, such as suicides, 26 cardiovascular diseases and cancers, all of which show unfavourable trends since the start of the crisis. Our analysis of amenable mortality points to more long-standing challenges that people in Greece might have experienced regarding access to and effectiveness of health care which were present even before the economic crisis. Thus, we found small but steady increases in a number of deaths from amenable conditions from 2000 onwards, suggesting that the crisis might have exposed systemic problems in the Greek health system which eventually led to an overall reversal in amenable mortality in Greece. Available evidence has documented fragmentation of coverage, a poorly developed primary care system, and lack of referral systems, along with poorly coordinated care across the care pathway. 27 These underlying challenges have been exacerbated by the changes imposed by the economic crisis, including a cut of 40% of overall public spending on health between 2009 and 2013, 1 coupled with exclusion of a large proportion of population from health coverage due to rising unemployment, as well as the sharply rising unmet medical need 28 observed since the start of the crisis. Others have suggested that an increase in mortality at older ages in Greece in 2011-12 may be linked to problems with accessing care, 29 while one study reported an increase in deaths due to adverse events associated with medical treatment. 30 Consequently, In Slovenia, the number of deaths from diabetes is 0 for some years; therefore, the cause has been excluded from joinpoint regression analysis.
deterioration in amenable mortality, along with other health outcomes, is not unexpected. From a broader perspective, our findings suggest that amenable mortality may be a relatively insensitive indicator of the impact of the economic crisis on the quality of healthcare. This is partly due to the inherent limitations of amenable mortality indicator overall: setting the widely accepted age limit at 75 years to minimize issues with coding of multi-morbidity excludes large number of potentially amenable deaths in older people, reduces the potential of detecting significant change when low levels have been achieved, and increases chances of random year-on-year fluctuations in specific amenable causes due to small numbers. In addition, amenable mortality captures only deaths thus missing the impact on morbidity. Moreover, given recent advances in health care, there is a need to keep the list of amenable causes under continuing review to accurately reflect the current capability of healthcare to prevent deaths. Concerning studying the impacts of the economic crisis, another set of limitations arises from the problem of defining the 'crisis', given how the range of possible economic indicators (GDP, employment, housing repossessions etc.) varied across countries, as did the extent to which cuts were directed at healthcare specifically, and differences in the ability of health system to withstand economic fluctuations. Finally, data availability and timeliness remains problematic, with many years of detailed mortality data missing even for high-income countries, leading to shorter or even interrupted timelines.
In summary, this study adds to the growing body of evidence showing that amenable mortality continues to decline across Europe. At the same time, it highlights increases of deaths from infectious diseases which should either be treatable or preventable in a small number of countries, and calls for investigation of the factors underlying these developments. Other causes for concern include respiratory conditions, as well as the sudden slowdown in the decline in mortality from stroke in Greece. Amenable mortality is a useful tool to highlight the presence of potential concerns about health systems performance, but its ability to detect the impact of changes in public spending on health care on the outcomes achieved by an individual health system is limited.
Supplementary data
Supplementary data are available at EURPUB online.
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Key points
Amenable mortality has declined in all EU countries between 2000 and 2015; however Estonia, Greece and Slovenia have seen a reversal in previously favourable trends in recent years.
Individual causes of death contributing to the reversal in amenable mortality suggest a complex picture but the rise in mortality from infectious diseases in at least three countries calls for further investigation.
Mortality trends in Greece show a sustained rise in deaths from a number of amenable causes, which predated the crisis, while progress stalled in reducing deaths from stroke corresponding to the onset of health expenditure cuts.
The use of amenable mortality to detect the impact of economic fluctuations on health system performance is limited, due to delayed data availability, ever-reducing scope for improvement, and the focus on death rather than other less adverse health outcomes.
Introduction
L ife expectancy (LE) at birth reflects the overall mortality level of a population. It summarizes the mortality patterns and health outcomes of various population groups such as women and men. Thus, LE can indicate health inequalities in the population. Even in the European Union (EU) with common goals and values and a common economic area, LE still differs between countries, and varies along sociodemographic variables. To reduce inequalities is a matter of fairness and as such should be of public interest.
This paper puts gender inequalities in the focus. In EU 28 Member States LE at birth reached 83.3 years (women) and 77.9 years (men) on average in 2015. 1 The gender gap in life expectancy (GGLE) at birth has narrowed from 6.4 years (2002) to 5.4 years (2015) on EU average but the size of this gender gap still varies substantially in Europe. 1 As biological differences appear to play a minor role in explaining the GGLE, 2, 3 differences in social relationships or health-risk behaviour gain attention. 4, 5 Men benefit more than women from the expansion of LE. For example, in the Netherlands, male LE increased between 1990 and 2015 by 8%, female LE by 4%. In other EU countries a comparable trend can be observed. As possible theoretical explanations for this trend, diminishment of gender inequality, 3 role expansion theory (undertaking of different social roles such as paid work, child care and household activities), 3 or convergence in unhealthy behaviours (reduction of risk behaviour in men, adoption of risk behaviour in women or both) are discussed. 4 Social relationships and health-risk behaviour are shaped by social norms but studies on the influence of societal factors on LE are rare. 6 Gender inequality, i.e. unequal distribution of wealth, power and benefits among women and men, is one of the most important societal factors. Gender inequality is socially determined and as such it is open to change by gender equality policies. 7 Some studies have shown an association between gender inequality and health indicators on a national or international level. Gender inequality is associated with child and infant mortality 8, 9 as well as with men's health. 3 Our paper addresses the question of whether gender inequality is also interrelated with the GGLE as well as to LE in both genders. The rationale is that gender differences in health related behaviours contribute to the gender gap in mortality and thus to LE, as behaviour is influenced by gender norms. We hypothesize that the GGLE is smaller in countries with more gender equality. With our analysis we want to contribute to the debate on reducing health inequalities between women and men.
Methods
We conducted an ecological study to investigate the association between gender inequality and (gender gap in) LE at birth in EU 28 Member States. To assess gender inequality we used the gender inequality index (GII) produced by the United Nations Development Programme with data from 2015 being the most recent available.
Gender inequality and the gender gap in life expectancy
